About Sagent Pharmaceuticals (NASDAQ:SGNT)
Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.
Industry, Sector and Symbol:
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Sector: Pharmaceuticals - NEC
- Symbol: NASDAQ:SGNT
- CUSIP: 78669210
- Web: www.sagentpharma.com
- Trailing EPS: ($0.77)
- Net Margins: -0.72%
- Return on Equity: -0.81%
- Return on Assets: -0.59%
- Outstanding Shares: 33,090,000
Frequently Asked Questions for Sagent Pharmaceuticals (NASDAQ:SGNT)
What is Sagent Pharmaceuticals' stock symbol?
Sagent Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGNT."
How were Sagent Pharmaceuticals' earnings last quarter?
Sagent Pharmaceuticals Inc (NASDAQ:SGNT) released its quarterly earnings results on Tuesday, May, 3rd. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.01 by $0.16. The business earned $67.30 million during the quarter, compared to analyst estimates of $74.30 million. Sagent Pharmaceuticals had a negative net margin of 0.72% and a negative return on equity of 0.81%. The firm's revenue for the quarter was down 17.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.04 earnings per share. View Sagent Pharmaceuticals' Earnings History.
Who are some of Sagent Pharmaceuticals' key competitors?
Some companies that are related to Sagent Pharmaceuticals include Johnson & Johnson (JNJ), Novartis AG (NVS), Pfizer (PFE), Merck & Company (MRK), Amgen (AMGN), Sanofi (SNY), Bristol-Myers Squibb Company (BMY), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), GlaxoSmithKline PLC (GSK), Astrazeneca PLC (AZN), Celgene Corporation (CELG), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP) and Teva Pharmaceutical Industries Limited (TEVA).
How do I buy Sagent Pharmaceuticals stock?
Shares of Sagent Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sagent Pharmaceuticals' stock price today?
One share of Sagent Pharmaceuticals stock can currently be purchased for approximately $21.76.
How can I contact Sagent Pharmaceuticals?
MarketBeat Community Rating for Sagent Pharmaceuticals (NASDAQ SGNT)MarketBeat's community ratings are surveys of what our community members think about Sagent Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sagent Pharmaceuticals' mailing address is 1901 N Roselle Rd Ste 700, SCHAUMBURG, IL 60195-3194, United States. The company can be reached via phone at +1-847-9081604.
Analysts' Consensus Ratings for Sagent Pharmaceuticals (NASDAQ:SGNT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|Consensus Price Target History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Analysts' Ratings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
(Data available from 11/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/11/2016||Deutsche Bank AG||Downgrade||Buy -> Hold||N/A|
|7/12/2016||Raymond James Financial, Inc.||Downgrade||Buy -> Market Perform||N/A|
|7/11/2016||Royal Bank Of Canada||Downgrade||Outperform -> Hold||N/A|
|7/11/2016||Piper Jaffray Companies||Downgrade||Overweight -> Neutral||$22.00 -> $21.75||N/A|
|6/17/2016||Jefferies Group LLC||Reiterated Rating||Hold||$13.00 -> $15.00||N/A|
|6/1/2016||J P Morgan Chase & Co||Reiterated Rating||Neutral||N/A|
|5/9/2016||Bank of America Corporation||Reiterated Rating||Hold||$13.00||N/A|
Earnings History for Sagent Pharmaceuticals (NASDAQ:SGNT)Earnings History by Quarter for Sagent Pharmaceuticals (NASDAQ SGNT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/3/2016||Q1||$0.01||($0.15)||$74.30 million||$67.30 million||View||N/A|
|2/16/2016||Q415||($0.02)||($0.55)||$78.13 million||$83.10 million||View||Listen|
|11/3/2015||Q315||($0.07)||$0.01||$73.84 million||$75.20 million||View||N/A|
|8/4/2015||Q215||$0.05||($0.01)||$83.28 million||$77.30 million||View||N/A|
|5/5/2015||Q115||$0.04||$0.04||$80.63 million||$82.60 million||View||N/A|
|2/19/2015||Q414||$0.01||$0.91||$76.20 million||$84.40 million||View||N/A|
|11/4/2014||Q314||($0.04)||$0.08||$64.01 million||$65.40 million||View||N/A|
|7/30/2014||Q214||($0.01)||$0.09||$67.14 million||$69.20 million||View||Listen|
|5/6/2014||Q114||($0.02)||$0.16||$65.66 million||$70.90 million||View||Listen|
|2/11/2014||Q4||($0.01)||$0.11||$60.25 million||$64.10 million||View||Listen|
|8/6/2013||Q2 2013||$0.46||$59.27 million||$59.60 million||View||N/A|
|5/6/2013||Q1 2013||($0.03)||$0.34||$55.31 million||$60.20 million||View||N/A|
|11/8/2012||Q312||($0.20)||($0.13)||$48.60 million||$49.40 million||View||N/A|
Earnings Estimates for Sagent Pharmaceuticals (NASDAQ:SGNT)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Sagent Pharmaceuticals (NASDAQ:SGNT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Sagent Pharmaceuticals (NASDAQ SGNT)Insider Trades by Quarter for Sagent Pharmaceuticals (NASDAQ SGNT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/21/2016||Ventures Fund V L.P. Vivo||Major Shareholder||Sell||2,005||$13.55||$27,167.75|| |
|11/4/2015||Ventures Fund V L.P. Vivo||Major Shareholder||Sell||603,177||$15.72||$9,481,942.44|| |
|11/3/2015||Vivo Ventures Vi, Llc||Major Shareholder||Sell||67,283||$16.32||$1,098,058.56|| |
|11/2/2015||Vivo Ventures Vi, Llc||Major Shareholder||Sell||93,523||$16.87||$1,577,733.01|| |
|1/27/2015||Morgan Stanley Investment Mana||Major Shareholder||Sell||78,041||$26.16||$2,041,552.56|| |
|1/23/2015||Morgan Stanley Investment Mana||Major Shareholder||Sell||211,883||$25.61||$5,426,323.63|| |
|1/21/2015||Morgan Stanley Investment Mana||Major Shareholder||Sell||69,316||$25.23||$1,748,842.68|| |
|1/16/2015||Morgan Stanley Investment Mana||Major Shareholder||Sell||125,000||$25.16||$3,145,000.00|| |
|1/14/2015||Morgan Stanley Investment Mana||Major Shareholder||Sell||100,000||$25.51||$2,551,000.00|| |
|10/8/2014||Robert J Flanagan||Director||Sell||16,000||$31.56||$504,960.00|| |
|10/7/2014||Robert J Flanagan||Director||Sell||8,000||$31.15||$249,200.00|| |
|9/25/2014||Robert J Flanagan||Director||Sell||16,000||$30.01||$480,160.00|| |
|9/24/2014||Robert J Flanagan||Director||Sell||8,000||$30.30||$242,400.00|| |
|9/12/2014||Robert J Flanagan||Director||Sell||16,000||$28.30||$452,800.00|| |
|9/11/2014||Robert J Flanagan||Director||Sell||8,000||$28.35||$226,800.00|| |
|8/28/2014||Robert J Flanagan||Director||Sell||16,000||$27.19||$435,040.00|| |
|8/27/2014||Robert J Flanagan||Director||Sell||8,000||$27.30||$218,400.00|| |
|8/12/2014||Robert J Flanagan||Director||Sell||16,000||$24.39||$390,240.00|| |
|7/31/2014||Robert J Flanagan||Director||Sell||16,000||$25.60||$409,600.00|| |
|7/18/2014||Robert J Flanagan||Director||Sell||16,000||$26.18||$418,880.00|| |
|7/2/2014||Robert J Flanagan||Director||Sell||16,000||$26.51||$424,160.00|| |
|6/18/2014||Robert J Flanagan||Director||Sell||16,000||$23.37||$373,920.00|| |
|6/4/2014||Robert J Flanagan||Director||Sell||16,000||$22.17||$354,720.00|| |
|5/22/2014||Robert Flanagan||Director||Sell||8,000||$22.02||$176,160.00|| |
|2/27/2014||Michael Logerfo||Insider||Sell||2,021||$21.43||$43,310.03|| |
|10/3/2013||Morgan Stanley Investment Mana||major shareholder||Sell||47,826||$20.27||$969,433.02|| |
|9/26/2013||Morgan Stanley Investment Mana||major shareholder||Sell||67,965||$20.37||$1,384,447.05|| |
|9/25/2013||Morgan Stanley Investment Mana||major shareholder||Sell||48,124||$21.30||$1,025,041.20|| |
|9/23/2013||Morgan Stanley Investment Mana||major shareholder||Sell||119,557||$21.83||$2,609,929.31|| |
|9/19/2013||Morgan Stanley Investment Mana||major shareholder||Sell||88,885||$22.53||$2,002,579.05|| |
|9/16/2013||Frank Kung||Director||Sell||1,161,717||$21.25||$24,686,486.25|| |
|9/16/2013||Jeffrey Yordon||CEO||Sell||85,813||$20.03||$1,718,834.39|| |
|9/16/2013||Vivo Ventures Vi, Llc||major shareholder||Sell||622,700||$21.25||$13,232,375.00|| |
|8/12/2013||Lorin Drake||VP||Sell||1,000||$23.69||$23,690.00|| |
Headline Trends for Sagent Pharmaceuticals (NASDAQ:SGNT)
Latest Headlines for Sagent Pharmaceuticals (NASDAQ SGNT)
|Corcept Therapeutics (CORT) and Sagent Pharmaceuticals (SGNT) Critical Analysis|
www.americanbankingnews.com - November 14 at 3:39 PM
|Head-To-Head Survey: Dr. Reddy's Laboratories (RDY) & Sagent Pharmaceuticals (SGNT)|
www.americanbankingnews.com - November 11 at 11:26 PM
|Sagent Pharmaceuticals (SGNT) vs. Astrazeneca PLC (AZN) Financial Review|
www.americanbankingnews.com - October 22 at 10:18 PM
|Financial Review: Innocoll Holdings PLC (INNL) versus Sagent Pharmaceuticals (SGNT)|
www.americanbankingnews.com - October 21 at 8:15 AM
|Reviewing Sagent Pharmaceuticals (SGNT) & Its Peers|
www.americanbankingnews.com - October 20 at 12:22 PM
|Analyzing Sagent Pharmaceuticals (SGNT) and Its Competitors|
www.americanbankingnews.com - October 18 at 9:42 AM
|Financial Analysis: Sagent Pharmaceuticals (SGNT) vs. Cellectar Biosciences (CLRB)|
www.americanbankingnews.com - October 15 at 10:38 AM
|Form 4 Sagent Pharmaceuticals, For: Aug 29 Filed by: Krizman Anthony|
www.streetinsider.com - September 1 at 7:13 PM
|Nichi-Iko Pharmaceutical Co., Ltd.|
www.thestreet.com - August 30 at 10:37 AM
|Nichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc.|
au.finance.yahoo.com - August 29 at 7:14 PM
|SAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delist|
biz.yahoo.com - August 29 at 7:14 PM
|Form SC TO-T/A Sagent Pharmaceuticals, Filed by: Shepard Vision, Inc.|
www.streetinsider.com - August 9 at 7:41 PM
|Nichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc.|
au.finance.yahoo.com - August 9 at 10:37 AM
|SAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - August 5 at 7:38 PM
Sagent Pharmaceuticals (NASDAQ SGNT) Chart for Friday, November, 17, 2017